Conversely, elevating canonical NF-κB activity by targeted knockdown of the NF-κB inhibitor cactus (cact, an IκB orthologue) (Geisler et al, 1992; Kidd, 1992) reduced trametinib efficacy in RasG12V tumours (Fig. 1E). The gene discussed is NFKB1; the disease is neoplasm.